BCAL Diagnostics Limited (ASX:BDX – Get Free Report) insider Jayne Shaw purchased 125,000 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were purchased at an average price of A$0.12 ($0.08) per share, with a total value of A$14,375.00 ($9,712.84).
BCAL Diagnostics Price Performance
The company has a current ratio of 3.60, a quick ratio of 6.70 and a debt-to-equity ratio of 17.74.
About BCAL Diagnostics
Want More Great Investing Ideas?
See Also
- Five stocks we like better than BCAL Diagnostics
- Why Are These Companies Considered Blue Chips?
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Insider Buying Explained: What Investors Need to Know
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Why is the Ex-Dividend Date Significant to Investors?
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for BCAL Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BCAL Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.